|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The Value of Capsule Endoscopy in Pediatric Patients with a Suspicion of Crohn’s Disease显示文摘 | F. Argüelles-Arias A. Caunedo J. Romero A. Sánchez M. Rodríguez-Téllez F. Pellicer F. Argüelles-Martín J. Herrerías | 2004 | Endoscopy2004，，10： | 1 |
| 2 | Usefulness of capsule endoscopy in patients with suspected small bowel disease显示文摘 | Caunedo A RodHguez-Tellez M Garcia-Montes JM | 2004 | Rev Esp Enferm Dig2004，96，： | 1 |
| 3 | Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy显示文摘 | Herrerias JM Caunedo A Rodriguez-Tellez M | 2003 | Endoscopy2003，35，7： | 1 |
| 4 | Macroscopic smallbowel mucosal injury caused by chronic mon- stery durgs(NSAID) use as assessed by caps- ule endoscopy显示文摘 | A Caunedo -Alvarez BJ Gomez - Rodriguez J Romero - Vazquez | 2010 | Rev Esp Enferm Dig2010，102，2： | 1 |
| 5 | Capsule endoscopy in patients with suspected Crohn' s disease and negative endoscopy 显示文摘 | Herrerlas JM Caunedo A Rodriguez-Tellez M | 2003 | Endoscopy2003，35，7： | 1 |
| 6 | Usefulness of capsule endoscopy in patients with suspected small bowel disease显示文摘 | Caunedo A Rodriguez-Tellez M Garcia-Montes JM | 2004 | Rev Esp Enferm Dig2004，96，1： | 1 |
| 7 | Modification of pepsinogen I levels and their correlation with gastrointestinal injury 'after administration of dexibuprofen, ibuprofen or diclofenac : a randomized, open-label, controlled clinical trial 显示文摘 | GOMEZ B J CAUNEDO A REDONDO L | 2006 | lnt J Clin Pharmacol Ther2006，44，4： | 1 |
| 8 | Comparison of a new chemiluminescent immunoassay for von Willebrand factor activity with the ristocetin cofactor‐induced platelet agglutination method显示文摘 | N. Cabrera A. Moret P. Caunedo A. R. Cid V. Vila F. Espa?a J. A. Aznar | 2013 | Haemophilia2013，，6： | 1 |
| 9 | Complications, limitations, and failures of capsule endoscopy: a review of 733 cases <ce:link locator='fx1'/>显示文摘 | Emanuele Rondonotti Juan Manuel Herrerias Marco Pennazio Angel Caunedo Miguel Mascarenhas-Saraiva Roberto de Franchis | 2005 | Gastrointestinal Endoscopy2005，，5： | 1 |
| 10 | The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's diseas显示文摘 | Argnlles-Arias F Caunedo A Bomero J | 2004 | Endoscopy2004，36，10： | 1 |
| 11 | Capsule endoscopy in patients with suspected Crohn's disease and negative endoscopy显示文摘 | Herrerias JM Caunedo A Rodriguez-Tellez M | 2003 | Endoscopy2003，35，7： | 1 |
| 12 | 胶囊内窥镜在疑似克罗恩病的患儿中的价值 | Argüelles-Arias F. Caunedo A. Romero J. J.M. Herreras 李康 | 2005 | 世界核心医学期刊文摘(胃肠病学分册)2005，0，2： | 0 |
| 13 | Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar(CT-P13)in patients with inflammatory bowel disease显示文摘BACKGROUND Infliximab original has changed the natural history of inflammatory bowel diseases(IBD) over the past two decades. However, the recent expiration of its patent has allowed the entry of the first Infliximab biosimilar into the European and Spanish markets. Currently switching drugs data in IBD are limited. AIM To compare the efficacy of infliximab biosimilar, CT-P13, against infliximab original, analyzing the loss of response of both at the 12 mo follow-up in patients with IBD.METHODS An observational study of two cohorts has been conducted. One retrospective cohort that included patients with IBD treated with Infliximab original, and a prospective cohort of patients who were switching from infliximab original to infliximab biosimilar(CT-P13). We had analyzed the overall efficacy and loss of efficacy in patients in remission at the end of one year after treatment with the original drug compared to the results of the year of treatment with the biosimilar.RESULTS98 patients(CD 67, CU 31) were included in both cohorts. The overall efficacy for infliximab original per year of treatment was 71% vs 68.2% for infliximab biosimilar(P = 0.80). The loss of overall efficacy at 12 mo for infliximab original was 6.6% vs 14.5% for infliximab biosimilar(P = 0.806). The loss of efficacy in patients who were in basal remission was 16.3% for infliximab original vs 27.1% for infliximab biosimilar. Adverse events were 9.2% for infliximab original vs 11.2% for infliximab biosimilar. CONCLUSION The overall efficacy and loss of treatment response with infliximab biosimilar(CT-P13) is similar to that observed with infliximab original in patients who were switching at the 12 mo follow-up. There is no difference in the rate of adverse events. | María Fernanda Guerra Veloz Federico Argüelles-Arias Luisa Castro Laria Belén Maldonado Pérez Antonio Benítez Roldan Raúl Perea Amarillo Vicente Merino Bohórquez Miguel Angel Calleja Angel Caunedo Alvarez Angel Vilches Arenas | 2018 | World Journal of Gastroenterology2018，24，46： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员